{"mainPropery":{"diseaseId":9362,"diseaseName":"Ovarian epithelial cancer","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9362/ovarian-epithelial-cancer","synonyms":["Ovarian cancer, epithelial","Epithelial ovarian cancer","EOC","Ovarian epithelial carcinoma"],"synonyms-with-source":[{"name":"Ovarian cancer, epithelial"},{"name":"Epithelial ovarian cancer"},{"name":"EOC"},{"name":"Ovarian epithelial carcinoma"}],"identifiers":[{"identifierType":"OMIM","identifierId":"604370"},{"identifierType":"UMLS","identifierId":"C0677886"},{"identifierType":"NCI Thesaurus","identifierId":" C4908"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":319,"resourceName":"Ovarian Cancer Research Alliance","abbreviation":"","address1":"14 Pennsylvania Plaza, Suite 2110","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10122","country":"United States","phone":"212-268-1002","tty":"","tollFree":"866-399-6262","fax":"202-331-2292","email":"info@ocrahope.org","url":"https://ocrahope.org","freeText":""},{"resourceID":320,"resourceName":"National Ovarian Cancer Coalition","address1":"2501 Oak Lawn Avenue, Suite 435","address2":"","address3":"","address4":"","address5":"","city":"Dallas","state":"TX","zip":"75219 ","country":"United States","phone":"214-273-4200 ","tty":"","tollFree":"888-OVARIAN","fax":"214-273-4201 ","email":"nocc@ovarian.org","url":"http://www.ovarian.org/"},{"resourceID":3366,"resourceName":"Minnesota Ovarian Cancer Alliance","abbreviation":"","address1":"4604 Chicago Ave ","address2":"","address3":"","address4":"","address5":"","city":"Minneapolis","state":"MN","zip":"55407","country":"","phone":"612-822-0500","tty":"","tollFree":"","fax":"","email":"INFO@MNOVARIAN.ORG","url":"http://mnovarian.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/604370' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=604370' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Ovarian epithelial cancer. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Ovarian+epithelial+cancer%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Ovarian epithelial cancer. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022260' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:167000' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/ovarian-cancer' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":8875,"phenoTypeName":"Breast carcinoma","percentRanges":"-"},{"phenoTypeId":8121,"phenoTypeName":"Multifactorial inheritance","percentRanges":"-"},{"phenoTypeId":6959,"phenoTypeName":"Ovarian neoplasm","percentRanges":"-"}],"medicalProducts":[{"productId":613,"genericName":"Bevacizumab","tradeName":"Avastin","tradeLink":"https://www.avastin.com/patient/mcrc.html","manufacturer":"","sponsor":"Genentech, Inc.","indication":"June 2018 approved in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, to treat patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. December 2016 approved either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, to treat patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/avastin","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a607001.html"},{"productId":616,"genericName":"Olaparib","tradeName":"Lynparza","tradeLink":"http://www.lynparza.com/","manufacturer":"","sponsor":"AstraZeneca Pharmaceuticals LP","indication":"December 2018, olaparib (Lynparza) received expanded approval for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza. Original approval was in August 2017.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/lynparza","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614060.html"},{"productId":717,"genericName":"Rucaparib","tradeName":"Rubraca","tradeLink":"https://www.rubraca.com/","manufacturer":"","sponsor":"Clovis Oncology, Inc.","indication":"April 2018 approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/rubraca","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a617002.html"},{"productId":668,"genericName":"Niraparib","tradeName":"Zejula","tradeLink":"http://zejula.com/","manufacturer":"","sponsor":"Tesaro, Inc.","indication":"Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/1038915-60-4","medlinePlusLink":""}],"EncodedName":"Ovarian_epithelial_cancer"}